Therapeutic	JJ
targets	NNS
in	IN
fibrotic	JJ
pathways	NNS
.	.

The	DT
pathogenetic	JJ
heterogeneity	NN
of	IN
pulmonary	JJ
fibrosis	NN
yields	NNS
both	CC
challenges	NNS
and	CC
opportunities	NNS
for	IN
therapy	NN
.	.

Its	PRP$
complexity	NN
implicates	VBZ
a	DT
variety	NN
of	IN
cellular	JJ
processes	NNS
,	,
signaling	NN
pathways	NNS
,	,
and	CC
genetics	NNS
as	IN
drivers	NNS
of	IN
disease	NN
.	.

TGF-b	NN
stimulation	NN
is	VBZ
one	CD
avenue	NN
,	,
and	CC
is	VBZ
central	JJ
to	TO
pro-fibrotic	JJ
protein	NN
expression	NN
,	,
leading	VBG
to	TO
decreased	VBN
pulmonary	JJ
function	NN
.	.

Here	RB
we	PRP
report	VBP
our	PRP$
recent	JJ
findings	NNS
,	,
introducing	VBG
the	DT
E3	NN
ligase	NN
Fibrosis	NNP
Inducing	NNP
E3	NN
Ligase	NN
1	CD
(	(
FIEL1	NN
)	)
as	IN
an	DT
important	JJ
regulator	NN
of	IN
TGF-b	NN
signaling	NN
through	IN
the	DT
selective	JJ
degradation	NN
of	IN
PIAS4	NN
.	.

FIEL1	NN
exacerbates	VBZ
bleomycin-induced	JJ
murine	JJ
pulmonary	JJ
fibrosis	NN
,	,
while	IN
its	PRP$
silencing	NN
attenuates	VBZ
the	DT
fibrotic	JJ
phenotype	NN
.	.

Further	RB
,	,
we	PRP
developed	VBD
a	DT
small	JJ
molecule	NN
inhibitor	NN
of	IN
FIEL1	NN
(	(
BC-1485	NN
)	)
that	WDT
inhibits	VBZ
the	DT
degradation	NN
of	IN
PIAS4	NN
,	,
and	CC
ameliorates	VBZ
fibrosis	NN
in	IN
murine	JJ
models	NNS
.	.

New	NNP
understanding	NN
of	IN
this	DT
pathway	NN
illustrates	VBZ
the	DT
many	JJ
targeting	VBG
opportunities	NNS
among	IN
the	DT
complexity	NN
of	IN
pulmonary	JJ
fibrosis	NN
in	IN
the	DT
continuing	VBG
search	NN
for	IN
therapy	NN
.	.

